Synopsis
Thanks to ramped up production in the year of vaccines, a realignment of geopolitical equations looks imminent. The focus will be on countries that make vaccines available and their recipients. While the history of China’s vaccines industry is riddled with controversies, being the supplier of affordable vaccines to low-and-middle income countries for decades makes India a better choice.
Clattering busily on the automated filling lines of the sprawling factory of Serum Institute of India in Pune are hundreds of bottles of Covishield, the Covid-19 vaccines that are getting ready to be shipped. From an inconspicuous existence for decades, the vaccines maker has shot to fame and grabbed international headlines. The meteoric climb comes from its potential to fan out millions of doses of its vaccines to every nook and cranny of the
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
Yearly
(Save 49%)
₹2499
15
Days Trial
+Includes DocuBay and TimesPrime Membership worth ₹1499 & ₹999 resp.
2-Year
(Save 63%)
₹3599
15
Days Trial
+Includes DocuBay and TimesPrime Membership worth ₹1499 & ₹999 resp.
Already a Member? Sign In now
Why ?
Sharp Insight-rich, Indepth stories across 20+ sectors
-
Access the exclusive Economic Times stories, Editorial and Expert opinion
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
